A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients

Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaran...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic and obstetric investigation 2019-01, Vol.84 (1), p.99-106
Hauptverfasser: Sfakianoudis, Konstantinos, Simopoulou, Mara, Nitsos, Nikolaos, Rapani, Anna, Pantou, Agni, Vaxevanoglou, Terpsithea, Kokkali, Georgia, Koutsilieris, Michael, Pantos, Konstantinos
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 106
container_issue 1
container_start_page 99
container_title Gynecologic and obstetric investigation
container_volume 84
creator Sfakianoudis, Konstantinos
Simopoulou, Mara
Nitsos, Nikolaos
Rapani, Anna
Pantou, Agni
Vaxevanoglou, Terpsithea
Kokkali, Georgia
Koutsilieris, Michael
Pantos, Konstantinos
description Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.
doi_str_mv 10.1159/000491697
format Article
fullrecord <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_491697</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2092536455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-fd2db805271821e17bb795d20dcd57ecfd204cf658fd4d1ccdfbe0b5f251af653</originalsourceid><addsrcrecordid>eNpt0M1LwzAYBvAgipvTg3eRgBc9VPPRrO1xDJ2DycZU0FNJkzdabZuZtIL_vRmbO3kKyfPLC--D0Ckl15SK7IYQEmd0mCV7qE9jxiNC2Ms-6hOepFHC42EPHXn_QUjAaXyIepxQHlzWR68jPJYe8CO4Ejy2DV5UsoUK2mhZqvf1zdcSL-HbVl1b2ka6H_wgG_kGNTQttgYvrHUB-JVtNDi8kG0ZEn-MDoysPJxszwF6vrt9Gt9Hs_lkOh7NIsV53EZGM12kRLCEpowCTYoiyYRmRCstElAhJ7EyQ5EaHWuqlDYFkEIYJqgMz3yALjdzV85-deDbvC69gqqSDdjO54xkTPBhLNb0akOVs947MPnKlXXYKKckXzeZ75oM9nw7titq0Dv5V10AZxvwKd0buB3Y_b_4N57MpxuRr7ThvwKkg1E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2092536455</pqid></control><display><type>article</type><title>A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Sfakianoudis, Konstantinos ; Simopoulou, Mara ; Nitsos, Nikolaos ; Rapani, Anna ; Pantou, Agni ; Vaxevanoglou, Terpsithea ; Kokkali, Georgia ; Koutsilieris, Michael ; Pantos, Konstantinos</creator><creatorcontrib>Sfakianoudis, Konstantinos ; Simopoulou, Mara ; Nitsos, Nikolaos ; Rapani, Anna ; Pantou, Agni ; Vaxevanoglou, Terpsithea ; Kokkali, Georgia ; Koutsilieris, Michael ; Pantos, Konstantinos</creatorcontrib><description>Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.</description><identifier>ISSN: 0378-7346</identifier><identifier>EISSN: 1423-002X</identifier><identifier>DOI: 10.1159/000491697</identifier><identifier>PMID: 30134239</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Adult ; Anti-Mullerian Hormone - blood ; Female ; Fertilization in Vitro ; Follicle Stimulating Hormone - blood ; Humans ; Infertility, Female - blood ; Infertility, Female - therapy ; Live Birth ; Novel Insights from Clinical Practice ; Oocytes ; Ovulation Induction - methods ; Platelet-Rich Plasma ; Pregnancy ; Pregnancy Rate</subject><ispartof>Gynecologic and obstetric investigation, 2019-01, Vol.84 (1), p.99-106</ispartof><rights>2018 S. Karger AG, Basel</rights><rights>2018 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-fd2db805271821e17bb795d20dcd57ecfd204cf658fd4d1ccdfbe0b5f251af653</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30134239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sfakianoudis, Konstantinos</creatorcontrib><creatorcontrib>Simopoulou, Mara</creatorcontrib><creatorcontrib>Nitsos, Nikolaos</creatorcontrib><creatorcontrib>Rapani, Anna</creatorcontrib><creatorcontrib>Pantou, Agni</creatorcontrib><creatorcontrib>Vaxevanoglou, Terpsithea</creatorcontrib><creatorcontrib>Kokkali, Georgia</creatorcontrib><creatorcontrib>Koutsilieris, Michael</creatorcontrib><creatorcontrib>Pantos, Konstantinos</creatorcontrib><title>A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients</title><title>Gynecologic and obstetric investigation</title><addtitle>Gynecol Obstet Invest</addtitle><description>Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.</description><subject>Adult</subject><subject>Anti-Mullerian Hormone - blood</subject><subject>Female</subject><subject>Fertilization in Vitro</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Humans</subject><subject>Infertility, Female - blood</subject><subject>Infertility, Female - therapy</subject><subject>Live Birth</subject><subject>Novel Insights from Clinical Practice</subject><subject>Oocytes</subject><subject>Ovulation Induction - methods</subject><subject>Platelet-Rich Plasma</subject><subject>Pregnancy</subject><subject>Pregnancy Rate</subject><issn>0378-7346</issn><issn>1423-002X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0M1LwzAYBvAgipvTg3eRgBc9VPPRrO1xDJ2DycZU0FNJkzdabZuZtIL_vRmbO3kKyfPLC--D0Ckl15SK7IYQEmd0mCV7qE9jxiNC2Ms-6hOepFHC42EPHXn_QUjAaXyIepxQHlzWR68jPJYe8CO4Ejy2DV5UsoUK2mhZqvf1zdcSL-HbVl1b2ka6H_wgG_kGNTQttgYvrHUB-JVtNDi8kG0ZEn-MDoysPJxszwF6vrt9Gt9Hs_lkOh7NIsV53EZGM12kRLCEpowCTYoiyYRmRCstElAhJ7EyQ5EaHWuqlDYFkEIYJqgMz3yALjdzV85-deDbvC69gqqSDdjO54xkTPBhLNb0akOVs947MPnKlXXYKKckXzeZ75oM9nw7titq0Dv5V10AZxvwKd0buB3Y_b_4N57MpxuRr7ThvwKkg1E</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Sfakianoudis, Konstantinos</creator><creator>Simopoulou, Mara</creator><creator>Nitsos, Nikolaos</creator><creator>Rapani, Anna</creator><creator>Pantou, Agni</creator><creator>Vaxevanoglou, Terpsithea</creator><creator>Kokkali, Georgia</creator><creator>Koutsilieris, Michael</creator><creator>Pantos, Konstantinos</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201901</creationdate><title>A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients</title><author>Sfakianoudis, Konstantinos ; Simopoulou, Mara ; Nitsos, Nikolaos ; Rapani, Anna ; Pantou, Agni ; Vaxevanoglou, Terpsithea ; Kokkali, Georgia ; Koutsilieris, Michael ; Pantos, Konstantinos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-fd2db805271821e17bb795d20dcd57ecfd204cf658fd4d1ccdfbe0b5f251af653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Anti-Mullerian Hormone - blood</topic><topic>Female</topic><topic>Fertilization in Vitro</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Humans</topic><topic>Infertility, Female - blood</topic><topic>Infertility, Female - therapy</topic><topic>Live Birth</topic><topic>Novel Insights from Clinical Practice</topic><topic>Oocytes</topic><topic>Ovulation Induction - methods</topic><topic>Platelet-Rich Plasma</topic><topic>Pregnancy</topic><topic>Pregnancy Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sfakianoudis, Konstantinos</creatorcontrib><creatorcontrib>Simopoulou, Mara</creatorcontrib><creatorcontrib>Nitsos, Nikolaos</creatorcontrib><creatorcontrib>Rapani, Anna</creatorcontrib><creatorcontrib>Pantou, Agni</creatorcontrib><creatorcontrib>Vaxevanoglou, Terpsithea</creatorcontrib><creatorcontrib>Kokkali, Georgia</creatorcontrib><creatorcontrib>Koutsilieris, Michael</creatorcontrib><creatorcontrib>Pantos, Konstantinos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic and obstetric investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sfakianoudis, Konstantinos</au><au>Simopoulou, Mara</au><au>Nitsos, Nikolaos</au><au>Rapani, Anna</au><au>Pantou, Agni</au><au>Vaxevanoglou, Terpsithea</au><au>Kokkali, Georgia</au><au>Koutsilieris, Michael</au><au>Pantos, Konstantinos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients</atitle><jtitle>Gynecologic and obstetric investigation</jtitle><addtitle>Gynecol Obstet Invest</addtitle><date>2019-01</date><risdate>2019</risdate><volume>84</volume><issue>1</issue><spage>99</spage><epage>106</epage><pages>99-106</pages><issn>0378-7346</issn><eissn>1423-002X</eissn><abstract>Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.</abstract><cop>Basel, Switzerland</cop><pmid>30134239</pmid><doi>10.1159/000491697</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-7346
ispartof Gynecologic and obstetric investigation, 2019-01, Vol.84 (1), p.99-106
issn 0378-7346
1423-002X
language eng
recordid cdi_karger_primary_491697
source MEDLINE; Karger Journals Complete
subjects Adult
Anti-Mullerian Hormone - blood
Female
Fertilization in Vitro
Follicle Stimulating Hormone - blood
Humans
Infertility, Female - blood
Infertility, Female - therapy
Live Birth
Novel Insights from Clinical Practice
Oocytes
Ovulation Induction - methods
Platelet-Rich Plasma
Pregnancy
Pregnancy Rate
title A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A07%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Case%20Series%20on%20Platelet-Rich%20Plasma%20Revolutionary%20Management%20of%20Poor%20Responder%20Patients&rft.jtitle=Gynecologic%20and%20obstetric%20investigation&rft.au=Sfakianoudis,%20Konstantinos&rft.date=2019-01&rft.volume=84&rft.issue=1&rft.spage=99&rft.epage=106&rft.pages=99-106&rft.issn=0378-7346&rft.eissn=1423-002X&rft_id=info:doi/10.1159/000491697&rft_dat=%3Cproquest_karge%3E2092536455%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2092536455&rft_id=info:pmid/30134239&rfr_iscdi=true